We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Vertex Pharmaceuticals ...

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $476.95, signifying a +1.45% move from its prior day's close.

Vertex Pharmaceuticals is all set to release its fiscal second-quarter earnings next month, and analysts project a robust ...

Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes ...

Vertex Pharmaceuticals (VRTX) reached $464.2 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $470.13, denoting a +2.54% move from the preceding trading day.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Over the last 7 days, the United States market has remained flat, yet it has experienced an 11% increase over the past year with earnings projected to grow by 15% annually. In this environment, ...

Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vertex Pharmaceuticals (VRTX) experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement ...

Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...